CytomX Therapeutics (CTMX) — AI Analysis & Mentions

CytomX's share price soared over 600% in a year, driven by drug pipeline optimism and analyst price targets up to $10. High volatility and a 24.98 P/E ratio mean the stock may be overvalued short-term, but its R&D pipeline warrants investor attention.